Intismeran plus pembrolizumab improves recurrence free survival in resected high risk melanoma

Share :
Published: 25 Oct 2026
Views: 245
Rating:
Save
Prof Georgina Long - Melanoma Institute Australia, Sydney, Australia

Prof Georgina Long speaks to ecancer about the phase III INTerpath-001 trial, which evaluated the personalised mRNA-based neoantigen therapy intismeran autogene combined with pembrolizumab versus pembrolizumab alone as adjuvant treatment for patients with resected stage IIB–IV melanoma.

Among 1,137 patients, the combination significantly improved recurrence-free survival, reducing the risk of recurrence or death by 42%, and distant metastasis-free survival, reducing the risk of distant metastasis or death by 38%.

At 24 months, recurrence-free survival was 82.2% with intismeran plus pembrolizumab compared with 70.0% with pembrolizumab alone.

Prof Long says the combination was generally well tolerated, although grade 3 or higher adverse events were slightly more frequent.

These findings highlight the potential of personalised neoantigen therapy to improve outcomes in high-risk melanoma following surgery.

This information is intended for health care professionals only. The information is not intended for US health care professionals.

Related Videos

UV1 vaccine combination shows no significant PFS improvement in BRCA wild type recurrent ovarian cancer

Dr Trine Jakobi Nøttrup - Copenhagen University Hospital, Copenhagen, Denmark
UV1 vaccine combination shows no significant PFS improvement in BRCA wild type recurrent ovarian cancer ( Dr Trine Jakobi Nøttrup - Copenhagen University Hospital, Copenhagen, Denmark )
24 Oct 2026

CD19 CD22 bispecific CAR T cell therapy achieves high response rates in R/R large B cell lymphoma

Prof Liang Wang - Beijing Tongren Hospital, Beijing, China
CD19 CD22 bispecific CAR T cell therapy achieves high response rates in R/R large B cell lymphoma ( Prof Liang Wang - Beijing Tongren Hospital, Beijing, China )
19 Jun 2026

Surovatamig plus rituximab induces high complete response rates in previously untreated follicular lymphoma

Prof Chan Cheah - Sir Charles Gairdner Hospital, Perth, Australia
Surovatamig plus rituximab induces high complete response rates in previously untreated follicular lymphoma ( Prof Chan Cheah - Sir Charles Gairdner Hospital, Perth, Australia )
18 Jun 2026

Romiplostim thrombopoietin receptor agonist rapidly restores platelet counts in acute ITP in 1L treatment during COVID 19

Dr Frederick Chen - Barts Health NHS Trust, London, UK
Romiplostim thrombopoietin receptor agonist rapidly restores platelet counts in acute ITP in 1L treatment during COVID 19 ( Dr Frederick Chen - Barts Health NHS Trust, London, UK )
18 Jun 2026

mRNA-4359 plus pembrolizumab shows high response rates and robust T-cell activation in melanoma

Dr Pavlina Spiliopoulou - Beatson West of Scotland Cancer Centre, Glasgow, UK
mRNA-4359 plus pembrolizumab shows high response rates and robust T-cell activation in melanoma ( Dr Pavlina Spiliopoulou - Beatson West of Scotland Cancer Centre, Glasgow, UK )
20 May 2026

Machine learning models improve prediction of immunotherapy outcomes across multiple cancer types

Dr Alyssa Pybus - Moffitt Cancer Center, Tampa, USA
Machine learning models improve prediction of immunotherapy outcomes across multiple cancer types ( Dr Alyssa Pybus - Moffitt Cancer Center, Tampa, USA )
28 Apr 2026

PRAME-targeted TCR therapy shows high response rates in metastatic uveal melanoma

Dr Sapna Patel - University of Colorado Anschutz, Aurora, USA
PRAME-targeted TCR therapy shows high response rates in metastatic uveal melanoma ( Dr Sapna Patel - University of Colorado Anschutz, Aurora, USA )
23 Oct 2025

Adjuvant pembrolizumab in resected merkel cell carcinoma shows improved distant metastasis-free survival

Dr Janice Mehnert - NYU Langone Health, New York, USA
Adjuvant pembrolizumab in resected merkel cell carcinoma shows improved distant metastasis-free survival ( Dr Janice Mehnert - NYU Langone Health, New York, USA )
20 Oct 2025

IO102-IO103 cancer vaccine plus pembrolizumab demonstrates PFS benefit in advanced melanoma

Dr Inge Marie Svane - Copenhagen University Hospital, Copenhagen Denmark
IO102-IO103 cancer vaccine plus pembrolizumab demonstrates PFS benefit in advanced melanoma ( Dr Inge Marie Svane - Copenhagen University Hospital, Copenhagen Denmark )
20 Oct 2025